CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cyramza Ramucirumab Cancelled
Onivyde Nanoliposomal Irinotecan Cancelled
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
Xeljanz tofacitinib Cancelled
Translarna ataluren Cancelled
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
Atriance Nelarabine Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Xolair Omalizumab Asthma, severe persistent Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete
Gynazole.1 Butoconazole nitrate Vaginal infection Do not list Complete
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
Last Updated : September 8, 2024